Intra-Platelet Platelet Factor 4 (IP.PF4) and the Heparin-Mobilisable Pool of PF4 in Health and Atherosclerosis

Summary

Some patients with clinical evidence of atherosclerosis and others with diabetes were compared with appropriate controls. The intraplatelet level of platelet factor 4 (PF4) was significantly decreased in the arteriopaths and was lower in the diabetics when compared with controls. Patients with transient ischaemic attacks and stroke have even lower values.

Intravenous heparin liberates large amounts of PF4 from an unknown reservoir, perhaps the endothelium, into the plasma. Arteriopaths liberated significantly more PF4 than the controls and the diabetics most. If a second heparin injection is given 24 hr after the first, the resultant plasma PF4 level was on average half that achieved after the first injection and again the patients had higher levels than the controls. Thus the reservoir originally “emptied” of PF4 by the heparin had been partially refilled in 24 hr and the reservoir in the atherosclerotic patients then contained more than the controls. Patients with atherosclerosis and especially diabetics differ from controls in the PF4 content of their platelets and in their response to heparin and in the rate of refill of the “heparin-mobilisable pool of PF4”.

Keywords

Intra-platelet PF4 - PF4 heparin response - Atherosclerosis - Diabetes - Transient ischaemic attacks

• References

• 1 Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76
• 2 Rao AK, Niewiarowski S, James P, Holt JC, Harris M, Elfenbein B, Bastl C. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 1983; 61: 1208-1214
• 3 Celia G, Colby SI, Taylor AD, McCracken L, Parisi AF, Sasahara AA. Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders. Thromb Res 1983; 29: 499-509
• 4 Bjoraker DG, Ketchan TR. Hemodynamic and platelet response to the bolus intravenous administration of porcine heparin. Thromb Haemostas 1983; 49: 1-4
• 5 Shuttleworth RD, O’Brien JR. Intraplatelet serotonin and plasma 5-hydroxyindoles in health and disease. Blood 1981; 57: 505-509
• 6 de Boer AC, Genton E, Turpie A. Chemistry, measurement and clinical significance of platelet specific proteins. Crit Rev in Clin Lab Sri 1982; 18: 183-211
• 7 van Oost BA, Veldhuyzen BF E, van Houwelingen HC, Timmermans AP M, Sixma JJ. Tests for platelet changes, acute phase reactants and serum lipids in diabetes mellitus and peripheral vascular disease. Thromb Haemostas 1982; 48: 289-293
• 8 Zahavi J, Kakkar VV. Beta-thromboglobulin - a specific marker of in vivo platelet release reaction. Thromb Haemostas 1980; 44: 23-29
• 9 Stewart ME, Douglas JT, Lowe GD O, Prentice CR M, Forbes CD. Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia. Lancet 1983; 1: 479-481
• 10 Mulley GP, Heptinstall S, Taylor PM, Mitchell JR A. ADP-induced platelet release reaction in acute stroke. Thromb Haemostas 1983; 50: 524-526
• 11 Kazmier FJ, Fuster V, Chesebro JH, O’Fallon WM, Palumbo PJ. Serial platelet survival half-life (PS) in peripheral vascular disease and diabetes mellitus. Thromb Haemostas 1981; 46: 288 (Abstr.)